CVR number 35040390
Industry 75.0000 Veterinary activities

JYSTRUP HESTEPRAKSIS ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  2.9% 1.6% 2.3% 2.3% 2.3%  
Credit score (0-100)  60 75 63 64 64  
Credit rating  BBB A BBB BBB BBB  
Credit limit (kDKK)  0.0 4.4 0.0 0.0 0.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  1,185 1,156 933 913 1,024  
EBITDA  440 635 150 211 257  
EBIT  390 585 99.6 172 207  
Pre-tax profit (PTP)  390.8 578.0 93.5 169.9 210.1  
Net earnings  304.8 449.5 72.4 132.0 164.1  
Pre-tax profit without non-rec. items  391 578 93.5 170 210  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  209 159 109 70.0 20.0  
Shareholders equity total  911 1,305 1,321 1,396 1,501  
Interest-bearing liabilities  0.0 0.0 0.0 9.1 0.1  
Balance sheet total (assets)  1,356 1,711 1,481 1,567 1,702  
Net Debt  -205 -703 -1,219 -783 -897  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,185 1,156 933 913 1,024  
Gross profit growth  34.4% -2.4% -19.3% -2.1% 12.1%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,356 1,711 1,481 1,567 1,702  
Balance sheet change%  41.6% 26.2% -13.4% 5.8% 8.6%  
Added value  440.3 635.0 149.6 221.7 256.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -100 -100 -100 -78 -100  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  32.9% 50.6% 10.7% 18.8% 20.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  33.8% 38.2% 6.2% 11.3% 12.9%  
ROI %  49.8% 52.8% 7.6% 12.6% 14.5%  
ROE %  38.8% 40.6% 5.5% 9.7% 11.3%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  67.2% 76.3% 89.2% 89.1% 88.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -46.6% -110.7% -815.3% -371.5% -349.5%  
Gearing %  0.0% 0.0% 0.0% 0.7% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 39.1% 0.1%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  2.6 3.8 8.6 8.8 8.4  
Current Ratio  2.6 3.8 8.6 8.8 8.4  
Cash and cash equivalent  205.3 703.1 1,219.4 791.7 896.7  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  702.7 1,147.2 1,211.9 1,325.7 1,480.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  440 635 150 222 257  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  440 635 150 211 257  
EBIT / employee  390 585 100 172 207  
Net earnings / employee  305 450 72 132 164